Connor, Clark & Lunn Investment Management (CC&L)’s Niagen Bioscience, Inc. Common Stock NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.9M | Buy |
823,325
+78,835
| +11% | +$1.14M | 0.04% | 355 |
|
|
2025
Q1 | $5.14M | Buy |
744,490
+238,304
| +47% | +$1.64M | 0.02% | 491 |
|
|
2024
Q4 | $2.69M | Buy |
506,186
+331,014
| +189% | +$1.76M | 0.01% | 652 |
|
|
2024
Q3 | $639K | Buy |
175,172
+17,115
| +11% | +$62.5K | ﹤0.01% | 1025 |
|
|
2024
Q2 | $431K | Buy |
158,057
+24,991
| +19% | +$68.2K | ﹤0.01% | 1087 |
|
|
2024
Q1 | $463K | Buy |
133,066
+16,553
| +14% | +$57.6K | ﹤0.01% | 1134 |
|
|
2023
Q4 | $167K | Buy |
116,513
+33,482
| +40% | +$47.9K | ﹤0.01% | 1283 |
|
|
2023
Q3 | $121K | Buy |
83,031
+45,618
| +122% | +$66.6K | ﹤0.01% | 1282 |
|
|
2023
Q2 | $58.7K | Buy |
+37,413
| New | +$58.7K | ﹤0.01% | 1267 |
|